SLC12A5 and epilepsy: The cultures were treated at either DIV4 with 10 μM staurosporine, a broad kinase inhibitor (Figure 3) or at DIV12 with 100 μM 4AP, a blocker of certain potassium channels and a model for epilepsy in vitro (Gonzalez-Sulser et al., 2011; Figure 4; Supplementary Figure 3), and subsequently, the expression of KCC2 whole protein, as well as its phosphorylation at S940 and T1007 were determined by immunofluorescence.